Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux Publication Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin…CertaraSeptember 1, 2013
Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin Publication Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo.…CertaraSeptember 1, 2013
Application of In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-based Pharmacokinetic Modeling to Investigate the Impact of the CYP2C8 Polymorphism on Rosiglitazone Exposure Publication Application of In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-based Pharmacokinetic Modeling to Investigate the Impact of the CYP2C8 Polymorphism on Rosiglitazone Exposure The purpose of this study was to predict the impact of the CYP2C8*3 genotype on…CertaraJune 1, 2013
Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Mice Publication Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Mice Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved as an immunosuppressant and for…CertaraMay 1, 2013
A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6 Publication A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6 Elevated cytokine levels are known to downregulate expression and suppress activity of cytochrome P450 enzymes…CertaraApril 10, 2013
Predicting Drug-drug Interactions: Application of Physiologically-based Pharmacokinetic Models Under a Systems Biology Approach Publication Predicting Drug-drug Interactions: Application of Physiologically-based Pharmacokinetic Models Under a Systems Biology Approach The development of in vitro-in vivo extrapolation (IVIVE), a 'bottom-up' approach, to predict pharmacokinetic parameters…CertaraMarch 1, 2013
Pharmacokinetics, Pharmacodynamics, Physiologically-based Pharmacokinetic Modeling of Monoclonal Antibodies Publication Pharmacokinetics, Pharmacodynamics, Physiologically-based Pharmacokinetic Modeling of Monoclonal Antibodies Development of monoclonal antibodies (mAbs) and their functional derivatives represents a growing segment of the…CertaraFebruary 1, 2013
Optimal Sampling Times for a Drug and Its Metabolite Using Simcyp Simulations as Prior Information Publication Optimal Sampling Times for a Drug and Its Metabolite Using Simcyp Simulations as Prior Information Since 2007, it is mandatory for the pharmaceutical companies to submit a Pediatric Investigation Plan…CertaraJanuary 1, 2013
Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer Publication Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer This investigation evaluated the utility of a physiologically based pharmacokinetic (PBPK) model, which incorporates model…CertaraDecember 1, 2012
A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6 Publication A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6 Pregnant women are usually not part of the traditional drug development program. Pregnancy is associated…CertaraOctober 9, 2012